Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
| Заболевание | Prostate Carcinoma |
|---|---|
| Фаза | Фаза 2 |
| Спонсор | Wake Forest University Health Sciences |
| Статус | Прекращено |
| Участники | 46 участн. |
| Вмешательство | Laboratory Biomarker Analysis, Propranolol Hydrochloride, Questionnaire Administration, Survey Administration |
| Дата начала | 15.01.2019 |
| Дата завершения | 15.06.2021 |
| Публикация результатов | 17.02.2025 |
Кратко
This randomized pilot clinical trial studies how well propranolol hydrochloride works in treating patients with prostate cancer who are undergoing surgery. When stressed, the body makes a molecule that may prevent tumor cells from dying, and propranolol hydrochloride may affect the signals in cells that cause tumor cells survival and death.
Mean Level of CREB Phosphorylation
| Group I (Propranolol Hydrochloride) | 1.34 ± .33 West blot band intensity,arbitrary units |
|---|---|
| Group II (no Treatment) | 1.43 ± .46 West blot band intensity,arbitrary units |
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate — Aragon Pharmaceuticals, Inc.
- Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced P — National Cancer Institute (NCI)
- M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castr — National Cancer Institute (NCI)
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abirate — Janssen Research & Development, LLC
- Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Ola — National Cancer Institute (NCI)
- A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Pr — Janssen Research & Development, LLC